|
Andrew, My apologies, however I have a conflict
and will not be able to attend. Thanks...Tom Office: 617-856-2682 Cell: 617-283-5200 From: eqdwg@xxxxxxxx
[mailto:eqdwg@xxxxxxxx] On Behalf Of Andrew
P Parry PLEASE NOTE : This meeting is tomorrow, to fit the diaries on many
active contributors * Telephone Conference US: 1 888 481 3032 Intl: 1 617 801 9600 Participant code: 8682747 * Agenda === 1. Action items from our last meeting 14:00 LDN Fri 04 Dec 2009 === AP contribute improved documentation for <currency> element of
underlyers such as Equity IY propose clarification of currency for various purposes on underlyer
( listing, trading ) IY propose further addition and correction of MCA and MCA Annex coding
scheme values IY add AEJ 2009 Closed Market Changes proposal from JC for FpML-4-7 IY add MEA II proposal from TA for FpML-4-7 === 2. Proposed new representatives === Please review CV / Bio. information circulated to the email list 2.1 Niraj Kumar, Wipro Technologies 2.2 Imthiyaz Sikkander, Barclays Capital 2.3 Mary Kwok, MarkitSERV New members should feel free to put questions to the group === 3. ISDA Legal Drafting === Ongoing ISDA "Legacy" Legal Drafting has several structural
consequences for FpML == 3.1 Multiple Exchange Annex ( MEA ) II Proposal : FpML-4-7, Q4 2009
== Open question ( IY/TA ) "The annex name is ‘Multiple Exchange Index Annex’ so
the scheme values should have the word ‘Index’. As for the element
and scheme names, it may not be essential to include ‘Index’ if we
want to keep them short, but I’d seek WG/Andrew’s opinion" [ AP : We should follow ISDA legal wording, they use
"MultipleExchangeAnnex", so we should call the element
<multipleExchangeAnnex> ] == 3.2 EU Index ( Client ) Swap : FpML-4-8, Q1 2010 == 3.2.1 Compounding Date Treatment and support ( CY ) "We are finalizing business logic for Q1 deliveries. For
Compounding, as of November 19th release, we added the Compounding field (you
would populate the Compounding field with "Y" when it's applicable). For Compounding Date, please confirm if the following logic works for
you. Compounding: Y Compounding Dates: [date] [date] [date] (you will list all relevant
dates) >>> this field is required when Compounding is populated with
Y. If you are planning to have a default for Compounding Dates in GTC,
then we can make this field optional. However, you still need to
"list" dates when you are submitting this field. Please kindly advise your thought on this by COB Tuesday (NY time) next
week." 3.2.2 Component Security Index Annex Not Applicable / Footnote. Could this evolve from a boolean (
Applicable / Not Applicable ) to a range of Annex values as per MEA ? == 3.3 PAISS : FpML-4-8, Q1 2010 == ISDA Counsel have made intensive efforts to solicit feedback and
finalise this draft Calls are scheduled 10:00 HKG on Tue 15 Dec 2009 and Thu 17 Dec to
discuss feedback == 3.4 Pre publication draft from ISDA Legal Department on Fri 11 Dec 2009 "Attached please find the pre-publication draft (clean and marked
versions) of Annex ISO to the 2009 Substantive edits to the draft have been made in respect of: • Exchange
– multiple exchange consequences have been provided for; • Settlement
Currency – specified as USD; • Futures Price
Valuation – language revised to provide for expiry dates that would fall
on a Saturday; • Latest Exercise
Time – Election added to the T-Supp; provisions added w/r/t multiple
exchanges and the Latest Exercise Time on an Expiration Date • Share
Adjustment Events – additional elections provided for under Cancellation
and Payment; • Stock Loan Rate
– field added for Agreed Model. Please review and provide any comments COB December 14 after which date
the document will be published." === 4. NY Fed OTC Commitments === === 5. Next Meeting === Propose 14:00 LDN Fri 08 Jan 2010 === 6. Thanks from the Chair === Thank you all for your contributions this year, we have collaborated to
deliver a very demanding book of work === 7. AOB === This communication is for informational purposes only. It is not intended as an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice. Any comments or statements made herein do not necessarily reflect those of JPMorgan Chase & Co., its subsidiaries and affiliates. This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. Thank you. Please refer to http://www.jpmorgan.com/pages/disclosures for disclosures relating to European legal entities. |